Fumiko Ladd Chino/bumpintheroad.us
Apr 6, 2025, 12:55
Fumiko Ladd Chino: Toxicity in phase III oncology clinical trials is often incompletely reported
Fumiko Ladd Chino, Radiation Oncologist at MD Anderson Cancer Center, shared an article by Avital M. Miller et al on X:
“Toxicity in phase III oncology clinical trials is often incompletely reported and is frequently minimized in its interpretation.
Only 1/3 reported Grade 1 to 2 toxicities and toxicity-minimizing language was used in 46% (subjectively downplay the harm of drugs).”
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials
Authors: Avital M. Miller et al
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 15:20
May 1, 2025, 14:51
May 1, 2025, 14:30
May 1, 2025, 14:00
May 1, 2025, 13:26
May 1, 2025, 13:03
May 1, 2025, 12:22